![]() |
Volumn 26, Issue 6, 2010, Pages 725-726
|
Poor Standardization in Platelet-Rich Therapies Hampers Advancement
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
PLATELET DERIVED GROWTH FACTOR;
ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION;
BIOCOMPATIBILITY;
BIOSAFETY;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
EUROPE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LETTER;
MEDICAL LITERATURE;
RANDOMIZED CONTROLLED TRIAL;
STANDARDIZATION;
THROMBOCYTE RICH PLASMA;
TREATMENT INDICATION;
ANTERIOR CRUCIATE LIGAMENT;
DOUBLE BLIND PROCEDURE;
EVIDENCE BASED MEDICINE;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
STANDARDS;
SURGERY;
TREATMENT OUTCOME;
ANTERIOR CRUCIATE LIGAMENT;
DOUBLE-BLIND METHOD;
EVIDENCE-BASED MEDICINE;
HUMANS;
PLATELET-RICH PLASMA;
PROSPECTIVE STUDIES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TREATMENT OUTCOME;
|
EID: 77952682207
PISSN: 07498063
EISSN: None
Source Type: Journal
DOI: 10.1016/j.arthro.2010.03.002 Document Type: Letter |
Times cited : (27)
|
References (4)
|